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Abstract
Fragile X-associated tremor/ataxia syndrome (FXTAS) is a progressive degenerative movement disorder characterized by kinetic tremor, cerebellar gait ataxia,
parkinsonism, and cognitive decline. This disorder occurs in both males and females, frequently in families with children who have fragile X syndrome. The clinical
features of this disorder, both classic and newly described, are summarized in this paper. In screening studies, fragile X mental retardation 1 (FMR1) gene
premutation (55–200 CGG) expansions are most frequently seen in men with ataxia who have tested negative for spinocerebellar ataxias. Since the original
description, the classic FXTAS phenotype has now been reported in females and in carriers of smaller (45–54 CGG) and larger (.200 CGG) expansions in FMR1.
Premutation carriers may present with a Parkinson disease phenotype or hypotension, rather than with tremor and/or ataxia. Parkinsonism and gait ataxia may also
be seen in individuals with gray zone (41–54 CGG) expansions. Studies regarding medication to treat the symptoms in FXTAS are few in number and suggest that
medications targeted to specific symptoms, such as kinetic tremor or gait ataxia, may be most beneficial. Great progress has been made in regards to FXTAS
research, likely given the readily available gene test and the screening of multiple family members, including parents and grandparents, of fragile X syndrome
children. Expansion of genotypes and phenotypes in the disorder may suggest that a broader disease definition might be necessary in the future.
Keywords: FMR1, FXTAS, genetics, ataxia, gray zone, premutation
Citation: Hall DA, O’Keefe JA. Fragile X-associated tremor ataxia syndrome: the expanding clinical picture, pathophysiology, epidemiology, and update on
treatment. Other Hyperkinet Mov 2012;2: http://tremorjournal.org/article/view/56
* To whom correspondence should be addressed. E-mail: Deborah_A_Hall@rush.edu
Editor: Elan D. Louis, Columbia University, United States of America
Received: August 8, 2011 Accepted: November 21, 2011 Published: May 11, 2012
Copyright: ’ 2012 Hall et al. This is an open-access article distributed under the terms of the Creative Commons Attribution–Noncommercial–No Derivatives License, which permits
the user to copy, distribute, and transmit the work provided that the original author(s) and source are credited; that no commercial use is made of the work; and that the work is not altered
or transformed.
Funding: This work was funded by NS052487 (D.H.), and a Parkinson Research Center grant from the Parkinson’s Disease Foundation.
Competing Interests: The authors report no conflict of interest.
Introduction
Fragile X-associated disorders cause significant morbidity and
include inherited intellectual disability, infertility, early menopause,
and a variety of neurodegenerative signs. Although pediatricians and
pediatric specialists were initially most likely to encounter individuals
with fragile X-associated disorders, the discovery of fragile X-
associated tremor/ataxia syndrome (FXTAS) has led older adults
with fragile X-associated movement disorders to adult neurologists for
diagnosis and treatment. This review summarizes the history of
FXTAS, the salient clinical features, epidemiology, pathophysiology,
newer clinical research findings in the disease, and approaches to
treatment.
Discovery of FXTAS
FXTAS, pronounced ‘‘fax-tas’’, was first discovered and reported in
2001 by Dr. Randi Hagerman, a developmental pediatrician, who
followed patients and their families in the Fragile X Clinic and
Research Program at the Children’s Hospital in Denver, Colorado.
Fragile X syndrome (FXS) is a neurodevelopmental disorder and is the
most common inherited cause of intellectual disability. It is caused by
an expansion (.200) in the trinucleotide (CGG) repeat elements
located in the promoter region of the fragile X mental retardation 1
(FMR1) gene. Dr. Hagerman received family reports of progressive
tremors, balance problems, frequent falling, and cognitive decline in
some grandfathers of children with FXS. After seeing tremor in several
of these grandfathers who were bringing their grandsons into the clinic,
she sent them to her colleague, Dr. Maureen Leehey (movement
disorders neurologist), at the University of Colorado and they
published the initial description of the disorder.1 These individuals
(and their daughters) have a fragile X ‘‘premutation’’, defined as 55–
200 CGG repeats in the 59-untranslated region of the FMR1 allele.2
The premutation can expand in later generations to a full mutation
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(.200 CGG repeats) and FXS. The name ‘‘fragile X- associated
tremor/ataxia syndrome (FXTAS)’’ was given to this new movement
disorder.2
Overview of the classic features of FXTAS
The classic phenotype of FXTAS is kinetic tremor and cerebellar
gait ataxia in male FMR1 premutation carriers over the age of 50.
Kinetic tremor is a common finding in persons with FXTAS but has
variable severity.3 In male carriers, at least 50% have mild tremor and
17% have moderate tremor, which can be similar in appearance to
essential tremor. In FXTAS patients with parkinsonism resting tremor
is uncommon, but 57% have mild bradykinesia and 71% have
rigidity.3 Clinical features also include peripheral neuropathy (60%),
impotence (80%), bowel and bladder dysfunction (30–55%), erectile
dysfunction, lower limb proximal muscle weakness, hearing loss, and
dysphagia.1–4 Progressive cognitive decline and neuropsychological
problems are common, including memory loss, anxiety, mood lability,
apathy, reclusive behavior/social phobias, and executive function
deficits.5–7 Significant dementia may occur as well.2 The cognitive
dysfunction in FXTAS is one of frontal-subcortical dementia that
typically develops after the onset of the movement disorder.8,9
Although kinetic tremor and cerebellar gait ataxia are the principle
clinical features of FXTAS, some patients may initially present with
other signs, such as peripheral neuropathy.10
Because of the variety of clinical symptoms in FXTAS and the fact
that the disorder has been recognized for a relatively short time,
patients with FXTAS are frequently initially diagnosed with other
disorders such as Parkinson disease (PD), tremor, ataxia, dementia,
and/or cerebrovascular disease.11 Diagnostic testing for FXTAS is
accomplished using polymerase chain reaction (PCR) to determine
FMR1 CGG repeat size. FMR1 PCR is highly sensitive and available
at many commercial and academic laboratories.
FXTAS tends to progress from mild ataxia and/or tremor to
disabling motor and cognitive impairments significantly compromising
the individual’s ability to function independently in society.3 FXTAS
has age-dependent penetrance, with approximately 30% of male
premutation carriers over the age of 50 having the disorder and over
75% of male premutation carriers over the age of 75 manifesting
symptoms.3,12 Individuals with small premutation alleles (,70 CGG
repeats) are much less likely to develop FXTAS.13
Individuals with FXTAS have distinct neuroimaging and neuro-
pathological profiles. Patients with FXTAS demonstrate moderate to
severe generalized brain atrophy with ventricular enlargement, specific
cerebellar atrophy, and subcortical and/or pontocerebellar white
matter lesions.2,14,15 While further research is needed, approximately
60% of males with FXTAS have white matter lesions or hyperinten-
sities on T2-weighted magnetic resonance imaging (MRI) in the
middle cerebellar peduncles, termed the ‘‘MCP sign’’(Figure 1).14 The
MCP sign is a major radiologic feature of FXTAS, but it has also been
reported in multiple system atrophy,16,17 recessive ataxia,17 and
acquired hepatocerebral degeneration.18 Recently, patients with
FXTAS have been shown to have significant pathology via diffusion
tensor imaging in multiple white matter tracts, including the middle
cerebellar peduncle, superior cerebellar peduncle, cerebral peduncles,
the fornix, and stria terminalis.19 After a study, including imaging, of
26 male premutation carriers with symptoms of FXTAS was
performed, provisional diagnostic criteria for FXTAS were proposed
based on clinical and radiological criteria (Table 1).2
Pathophysiology of FXTAS
Intranuclear inclusions in both neurons and astrocytes throughout
the cerebrum (most numerous in the hippocampus), in the thalamus,
basal ganglia (including the substantia nigra), inferior olive and dentate
nuclei are found via postmortem analysis in the brains of individuals
with FXTAS (Figure 2).20 The spinal cord, autonomic ganglia and
cranial nerve nucleus XII also demonstrate intranuclear inclusions.21
Although Purkinje cells rarely have inclusions, there is neurodegenera-
tion in the cerebellum, with marked Purkinje cell loss, axonal swelling,
and gliosis. Recent reports show widespread non-central nervous
system organ pathology, including inclusions, in the endocrine organs,
gastrointestinal tract, heart, and kidney.22
Figure 1. Axial Fluid Attenuated Inversion Recovery (FLAIR) Magnetic Resonance Imaging in a FXTAS Patient.(A) Hyperintensity in the middle cerebellar peduncle;
(B,C) global volume loss with scattered white matter hyperintensities. FXTAS, Fragile X-associated tremor ataxia syndrome.
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Research into the pathophysiological mechanisms causing FXTAS
is progressing at a rapid pace. The full FMR1 mutation (.200 CGG
repeats) causes hypermethylation and transcriptional silencing of the
FMR1 gene and lack of its protein product, fragile X mental
retardation protein (FMRP), an important modulator of neural
development and synaptic plasticity. However, premutation carriers
(55–200 repeats) have elevated FMR1 mRNA levels and compelling
evidence suggests that excess mRNA causes a neurotoxic gain of
function effect, which is very different mechanistically than what
occurs in full mutation carriers. Those with allele repeat sizes between
55 and 100 have a two- to fourfold increase in FMR1 mRNA levels
and low normal to normal levels of FMRP in blood lymphocytes, while
those with longer CGG repeats (100–200) have 4–10 times elevated
FMR1 mRNA and mildly reduced FMRP levels.23 Incidentally, female
premutation carriers also have elevated mRNA levels even though
FXTAS was originally thought to be found only in males.24,25 The
RNA toxic gain of function may dysregulate neuronal and astrocyte
function and cause eventual cell death. This occurs in numerous places
including the limbic system, cerebral cortex, cerebellum, brainstem,
and peripheral autonomic ganglia.26 Greater RNA toxic effects may
be associated with molecular findings, as larger repeat sizes correlate
positively with degree of central nervous system neuropathology,27 and
higher repeat sizes and mRNA levels correlate positively with electrical
measures of peripheral neuropathy.28 FMR1 mRNA has been detected
in the ubiquitin-positive intranuclear inclusions found in neurons and
astrocytes throughout the brain of FXTAS patients, adding credibility
to the role of RNA toxicity in the disorder.29
Epidemiology of FXTAS
The FMR1 premutation occurs in approximately 1/250 females and
1/800 males, while the full mutation is much more rare (1/2500–
4000).30–32 Ongoing newborn screening studies may increase the
prevalence as diagnostic methods have improved since some of these
large population screening studies were conducted. Once FXTAS was
described, many neurologists screened banked DNA or tested patients
sequentially to identify premutation carriers in their clinic populations.
Most of the studies focused on phenotypes that were reported in the
original case series, such as tremor, ataxia, or parkinsonism. Twenty-
nine studies have now reported the results of screening movement
disorder patients for FMR1 expansions.33–62 These screening studies
include patients with ataxia,33–34,46,48,52,56,61,62 spinocerebellar ataxia
(SCA),40–41,45–46,54–55,57–58 multiple system atrophy,36,50,58,60
Table 1. Diagnostic Criteria for FXTAS
Molecular FMR1 CGG Repeat Size 55–200
Clinical
Major signs Intention tremor
Gait ataxia
Minor signs Parkinsonism
Moderate to severe short term memory deficits
Executive function deficits
Radiological
Major signs MRI white matter lesions in the middle cerebellar peduncle (MCP sign)
Minor signs MRI white matter lesions in cerebral white matter
Moderate to severe generalized atrophy
Diagnostic Categories
Definite Presence of one major radiological sign plus one major clinical symptom
Probable Presence of either one major radiological sign plus one minor clinical symptom
or has two major clinical symptoms
Possible Presence of one minor radiological sign plus one major clinical symptom
Abbreviations: FMR1, fragile X mental retardation 1; FXTAS, Fragile X-associated tremor/ataxia syndrome; MCP, middle cerebellar peduncles; MRI, magnetic resonance
imaging
Adapted from Jacquemont et al, 2003.2
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Friedreich’s ataxia,40 parkinsonism,37,41,44,47,49–51,56,62 autonomic
dysfunction,36 essential tremor,35,51,58,62 and Huntington disease-like
phenotypes.42,43
The prevalence of premutation range expansions ranged from 0 to
4% in individuals with ataxia,33,40,42,46,48,52,55–59,61 with the highest
proportions seen in adult onset ataxia (2.2%),34 ataxia patients with
negative SCA gene testing (4%),45 and male ataxia patients with
negative SCA testing (5%).54 Premutation frequencies ranged from 0
to 4% in multiple system atrophy36,38,58,60 and 0 to 1% in
parkinsonism cohorts.37,39,41,44,47,49,53,56,62 No premutation carriers
were ascertained in essential tremor patients35,51,58,62 or Friedreich’s
ataxia patients.40
These prevalence suggest that FMR1 premutation expansions are
not a significant cause of movement disorders in these populations.
The reasons for this may be that these studies excluded individuals
with the premutation phenotype. For example, many PD DNA
repositories exclude individuals with cerebellar signs. Other reasons
may include lack of insight of patients with FXTAS into their
neurological symptoms and the fact that very few are referred to
movement disorder specialists.11
FXTAS in females and full mutation carriers
Since the original description of FXTAS, there have been case
reports and studies that describe phenotypes that vary from the
original diagnostic criteria (Table 1). Although FXTAS was originally
described in males, females with FXTAS have now been reported. The
first study described five female premutation carriers who had tremor
and ataxia, but only one had a MCP sign on MRI.25 Subsequent
studies suggest that only 13% of females affected with FXTAS have the
MCP sign.63 Initial case–control studies did not show an association of
tremor and ataxia in female premutation carriers,12,64 likely because of
lower manifestation of signs due to X-inactivation effects. However,
the penetrance of FXTAS in female premutation carriers may be
closer to 16.5% in families with other identified fragile X-associated
disorders.65 More recent case reports have described female carriers
with typical FXTAS,66 with FXTAS and spasmodic dysphonia67 and
with FXTAS and multiple sclerosis.68 Interestingly, a 23-year-old
female premutation carrier (CGG5100) was reported with autism,
levodopa-responsive parkinsonism, ataxia, and hyperintensities on T2-
weighted MRI images in the basis pontis and MCP.69
Other medical comorbidities may be more common in female
premutation carriers with and without FXTAS, to include thyroid
disease, hypertension, seizures, and fibromyalgia,70 but a similar study
done by another group did now show these associations.71
Additionally, daughters of males with FXTAS are more likely to
report balance problems and neurological symptoms than daughters of
premutation carrier fathers without FXTAS,72 suggesting that
secondary gene effects, ascertainment, or other issues may be causing
the conflicting results.
Evidence now suggests that full FMR1 mutation carriers may also
have signs or symptoms of FXTAS. The pathophysiology of FXTAS is
thought to involve toxic FMR1 mRNA and full mutation carriers have
little or no FMR1 mRNA, so they are not expected to develop FXTAS.
However, individuals with the full mutation that have size mosaicism
(cells that have different sizes of CGG expansions) or an unmethylated
mutant allele (which is transcribed), would be at risk for FXTAS given
the presence of toxic mRNA.
Figure 2. FXTAS Pathology. (A) Hematoxylin and eosin-stained sections of
cerebrum with eosinophilic neuronal intranuclear inclusions ranging in size from 2
to 5 mm (original magnification 10006). (B) Intranuclear inclusions stained with
anti-ubiquitin antibodies (original magnification 10006). FXTAS, Fragile
X-associated tremor ataxia syndrome.
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FXTAS was reported in a male carrier of an unmethylated full
mutation in the FMR1 gene.73 The 65-year-old alcoholic FMR1
mutation carrier (CGG 297–480) had a 10-year history of cerebellar
gait ataxia, kinetic tremor, parkinsonism, and cognitive decline. In
addition, he had the MCP sign and met criteria for FXTAS, with the
exception of a CGG repeat size larger than the premutation range.
Rare intranuclear inclusions have also been reported in the brains of
three older adult males with FXS, one of whom had gait ataxia and
parkinsonism.22 This man had CGG repeat sizes of 339–1225, but
without a MRI report, it is unclear if he met diagnostic criteria for
FXTAS (Table 1).
Other features seen in premutation carriers
Premutation carriers may have other clinical features or neurolo-
gical symptoms but not meet criteria for FXTAS. Although individuals
with FXTAS frequently have parkinsonism, many of them have
features unusual for idiopathic PD, like the presence of cerebellar gait
ataxia and prominent kinetic tremor. However, there have now been
reported FMR1 premutation carriers with a PD phenotype who lacked
cerebellar gait ataxia, responded to dopaminergic medications, and
even developed motor fluctuations.74 Three FMR1 expansion carriers
with parkinsonism with normal 2b-carbomethoxy-3b-(4-iodophenyl)
tropane single photon emission computed tomography (b-CIT
SPECT) imaging suggest that the parkinsonism related to premutation
carrier status may not be a presynaptic dopamine deficit, unlike typical
PD.75 White matter changes in the basis pontis, in addition to the
MCP sign, have also been reported in two male premutation carriers:
one with a PD phenotype and one with typical FXTAS.15
Several other case reports illustrate the heterogeneity of neurological
phenotypes in adult FMR1 premutation carriers. Two patients
presenting with postprandial hypotension have been described: one
with kinetic tremor and the MCP sign and the other having a PD
diagnosis with falls and syncope.76,77 The latter case had intraneuronal
inclusions, characteristic of FXTAS on autopsy.78 Another FMR1
premutation carrier with prominent paraparesis, hyperreflexia, and
flexor plantar responses was described,48 but these signs have not been
described in other premutation carriers.
Premutation carriers who do not have FXTAS can have other signs
typically seen in FXS; including intellectual disability, autism,
hyperactivity, perseverative behaviors, and tactile defensiveness.78
Seizures were more common in premutation carriers than in controls
in a family survey.79 In addition, cognitive deficits can be seen across
the life span in premutation carriers without FXTAS.6,7,80 Specific
executive function and memory deficits are observed, including poor
inhibitory control, working memory deficits, and poor planning skills.6
It has been proposed that these early cognitive impairments may be
indicative of later onset of FXTAS.6 However, other groups have not
found this association.81
Some asymptomatic male premutation carriers have brain (includ-
ing hippocampal) atrophy, reduced brainstem size, and ventricular
enlargement that may be early predictors of FXTAS development.27,82
In addition, reduced hippocampal volume correlates with anxiety in
female premutation carriers and with paranoia in carrier males, with
and without FXTAS.63 Brain imaging studies have shown that male
premutation carriers with cognitive and psychiatric dysfunction (but
not full FXTAS) demonstrate reduced amygdala activation when
viewing fearful faces83 and reduced hippocampal activation during
recall tasks.84
Gray zone controversies
Smaller expansions in the FMR1 gene have been termed ‘‘gray
zone’’ or intermediate alleles based on the lower likelihood of the CGG
repeat increasing and causing FXS in later generations. Gray zone
alleles have been reported to expand over two generations to a full
mutation, but typically it takes at least three generations.85–87 The
American College of Medical Genetics practice guidelines define the
intermediate zone or gray zone alleles as 41–60 CGG repeats.88
However, 45–54 CGG repeats have been designated the intermediate
or gray zone by the laboratory practice committee of the American
College of Medical Genetics.89,90 This discrepancy in the definition of
the gray zone has become more important given that several studies
are now reporting phenotypes associated with gray zone or
intermediate allele sizes. The prevalence of repeat expansions is
0.3% in the 41–54 CGG range and 2.6% in the 40–59 range in the
general population.30,32,91 Gray zone carriers of 45–54 CGG repeats
can have up to 1.5-fold increase in FMR1 mRNA, with transcript levels
of FMR1 mRNA starting to increase at just 39 CGG repeats.92
Gray zone alleles have been associated with special educational
needs in children and primary ovarian insufficiency, similar to
phenotypes seen in larger repeat expansion carriers.93,94 Gray zone
expansions have also been reported in some movement disorder
populations. The prevalence of gray zone expansion vary, with
proportions of around 1% reported in studies screening individuals
with a multiple system atrophy phenotype,36 1–7.5% in individuals
with parkinsonism,44,49,53 and 0–11% in idiopathic PD.47,50–51,62
However, the studies were mixed in whether the proportions of gray
zone expansions were elevated relative to control patients collected in
the studies.50,53,62 Gray zone expansions were reported in 5% of
individuals with late onset cerebellar ataxia after the age 50 (with
negative SCA testing),61 1.5% in those with essential tremor,51 and 3%
in a mixed cohort of males with ataxia, parkinsonism, and tremor.56 A
screen of 228 Australian males with PD showed a rate of 7.5% CGG
gray zone alleles compared to 3% gray zone alleles in 578 consecutive
newborns.53 A second study showed 11% of 98 females with PD had
gray zone alleles (41–54 repeats) compared to female controls at 4.4%,
with an odds ratio of 3.23 (p50.019).62 In contrast, a similar screening
study in southern Spain showed that 206 PD patients and 227 controls
both had a rate of 6% gray zone alleles (45–54 CGG repeats).50
A study of a family of FMR1 repeat expansion carriers with broad
clinical involvement describes a gray zone carrier with 52 CGG
repeats with subtle tremor and balance problems, but milder than
what is seen in FXTAS.78 Imaging was not reported. In addition, three
gray zone carriers who meet criteria for FXTAS have been
described.62 Like the earlier studies, which may expand the phenotype
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of FXTAS, better characterization of gray zone carriers with
neurological signs and symptoms may show that these individuals also
have a FXTAS-like phenotype or other fragile X-associated movement
disorders.
The description of individuals with genotypes or phenotypes that
do not fit into the original diagnostic criteria of FXTAS suggest
that the definition of FXTAS may need to be broadened. Clinical
and genetic heterogeneity frequently increases in newly described
genetic disorders as additional cases are identified so this is not
unexpected.
Treatment
Currently, there are no specific disease-modifying medical treat-
ments for patients with FXTAS. Theoretically, drugs that would
prevent or counteract the excess of FMR1 mRNA might be beneficial
in preventing the neurotoxic cascade. Studies have shown that histone
acetyltransferase inhibitors reduce FMR1 mRNA to normal levels and
suppress CGG repeat neurotoxicity in a Drosophila model of
FXTAS.95 This may lead to histone acetylation modulating drugs or
other pharmaceuticals that normalize FMR1 mRNA levels in future
clinical trials for FXTAS.
The present medical management of patients with FXTAS is
limited to medications employed to alleviate the symptoms of tremor,
ataxia, mood changes, anxiety, cognitive decline and/or dementia,
neuropathic pain and/or fibromyalgia. Some patients with FXTAS
have shown improvement in gait ataxia with amantadine in
anecdotal reports,96 varenicline at 0.5–1 mg per day (n51),97 or
with riluzole 100 mg daily (n51).98 However, anecdotal reports
suggest that varenicline may exacerbate tremor and psychiatric
symptoms in some patients.99 The most comprehensive medication
study conducted in FXTAS was a questionnaire study where 58
FXTAS patients rated improvement in various neurological symp-
toms.100 Many patients (70%) with possible or probable FXTAS
were not taking medications for their symptoms. However, some
FXTAS patients with both ataxia and parkinsonism subjectively
reported dopaminergic medications improved their balance.100 Beta-
blockers, primidone, and topiramate are used to treat essential
tremor and these were found to subjectively improve kinetic tremor
in other FXTAS patients.100 Levetiracetam has also been reported to
help kinetic tremor in a FXTAS patient in a case report.101 Because
anxiety and stress aggravate or worsen tremor, benzodiazepines
might be beneficial in certain patients, especially those with anxiety
disorders.3
A slowing of cognitive decline in individuals with FXTAS using
acetylcholinesterase inhibitors has been reported by caregivers.100
Combination therapies of donepezil and venlafaxine for a 2-year
duration have been reported to improve and stabilize the dementia
and mood alterations (depression, anxiety, agitation, hostility, and
irritability) in a case report of a FXTAS patient who had multiple
neurological symptoms.102 Venlafaxine has been reported anecdotally
to be useful for treating depression, anxiety, agitation, hostility, and
irritability in a few patients with FXTAS.103 Recently, a combination
of memantine and venlafaxine treatment was found to improve
tremor, balance, neuropathy, depression, anxiety, and cognitive
function (auditory recall, oral word association, and executive
functions) in case report of a female with FXTAS.104
Neurological rehabilitative therapies have not been studied
specifically in FXTAS but should be considered in treatment. Those
with dysphagia have an increased risk of aspiration and in these cases
routine monitoring of swallowing by a speech therapist, including
barium swallowing tests, is indicated,105 and appropriate feeding
therapy should be provided. In patients who develop dysarthria,
speech therapy may be beneficial, especially in finding means of
augmentative or alternative communication. FMR1 premutation
carriers may be at higher risk to have hearing loss so those affected
should be referred to audiology for testing and provision of hearing
devices if appropriate.
Occupational and physical therapy may be beneficial for FXTAS
patients with tremor, gait and balance deficits, poor mobility, and
difficulty performing functional tasks. Assistive technology to aid
feeding and computer use in patients with intention tremor is
frequently employed by neurorehabilitation specialists.106,107
Increasing the inertia or viscoelastic resistance of a limb will dampen
kinetic tremors and gait ataxia due to cerebellar disease.108,109
Interventions directed at this include trunk or extremity loading with
weights109–112 and use of trunk vests and Lycra garments to provide
proximal limb and trunk stability.113–115 Disability scores and quality
of life stabilized and depression improved in patients with SCA3 after
15 sessions of occupational therapy using coordination exercise
protocols and these effects lasted for at least 6 months after
treatment.116
Significant improvements in balance, gait ataxia, and stable
achievement of activities of daily living were found following a 4-
week intensive physical therapy program in patients with degenerative
cerebellar ataxias of varying causes.117 Moreover, these changes
persisted, albeit at a lower level, for 1 year during which time the
patients performed a daily home exercise program, despite an increase
in ataxia and gradual decline in motor performance over this same
time period.118 These researchers suggest that the improvements
achieved by training were equivalent to gaining back functional
performance of 2 years of neurodegenerative disease progression. Body
weight supported treadmill training for gait deficits including
ataxia119–125 and specific balance protocols using computerized
dynamic posturography (CDP) with biofeedback retraining devices
based on altering visual, somatosensory, and vestibular feedback are
relatively newer devices used in the treatment of patients with balance
disorders126–131 and may be helpful in FXTAS patients.
Many men with FXTAS report dizziness3 as well as female
premutation carriers without FXTAS.132 It is not yet known whether
this is due to orthostasis, vestibular dysfunction, or both.3 Testing with
CDP would help determine whether dizziness is related to vestibular
function and could be treated with vestibular rehabilitation protocols
by specialized balance therapists.
Hall DA, O’Keefe JA The Expanding Clinical Picture of FXTAS
Tremor and Other Hyperkinetic Movements
http://www.tremorjournal.org
The Center for Digital Research and Scholarship
Columbia University Libraries/Information Services6
Summary/Discussion
Given the discovery of FXTAS in 2001, the advancement of
knowledge in this disorder has occurred very quickly. Extensive
cascade genetic testing, where testing in families with FXS probands
leads to the identification of obligate premutation carriers and at-risk
individuals, has accelerated the research advances in this field. The
willingness of premutation carriers to participate in research and the
collaboration of fragile X experts has also been beneficial. There are
currently several studies testing agents to normalize molecular
pathways in FXS. Our hope is that studies with agents that target
the premutation pathologies are not far behind.
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